General information

Development

Microinjection of a gene fragment containing the human interleukin-3 (hIL-3) encoding sequence into fertilized eggs of NPG mice, followed by genotyping to obtain F0 generation positive mice. These F0 generation positive mice were bred with NPG mice to produce F1 generation mice. By detecting the expression levels of hIL-3 in the offspring of F1 generation positive mice, the desired strain was obtained.

The hIL-3 cytokine is expressed in NPG mice, stimulating the differentiation of multipotent hematopoietic stem cells into myeloid progenitor cells. Together with NPG mice expressing human GM-CSF and M-CSF cytokines, stable and widespread myeloid and lymphoid cell differentiation can be formed in the peripheral blood, bone marrow, thymus, spleen, and non-lymphoid tissues including lungs and liver, 6-8 weeks after transplanting human CD34+ hematopoietic stem cells. In the blood and tissues, granulocyte differentiation (basophils, neutrophils, and mast cells), antigen-presenting cell differentiation (dendritic cells and macrophages), and regulatory T cell populations can be detected, among others. 

Genotype identification information

Fig1. Genotyping of NPG-hIL3

Phenotype

1. Protein expression analysis

Fig2. Human IL3 expression analysis in heterozygous NPG-hIL3 mice by ELISA. 

Serum were collected from heterozygous NPG-hIL3 mice, and analyzed by ELISA with human IL3 ELISA kit. hIL-3 expression was approximately 52.8 pg/mL in heterozygous NPG-hIL3.

NPG-hIL3 Mice Applications

1.Immunotherapy

2.Tumor research

3. Inoculation of human tumors for screening of relevant drugs

4. Preparation of humanized mouse models of the immune system, such as those obtained by inoculation with PBMC, PBNK and HSC

5. Research on human hematopoietic system and immune system

6. Human cell and tissue transplantation

Reference

1. Ito R, et al. Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol. 2013, 191(6):2890-2899.

2. Wunderlich M et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010, 24(10):1785-1788.

3. Billerbeck E, et al. Development of human CD4⁺FoxP3⁺ regulatory T cells in human stem cell factor^-, granulocyte-macrophage colony-stimulating factor^-, and interleukin-3-expressing NOD-SCID IL2R{gamma}null humanized mice. Blood. 2011, 117(11):3076-3086.

4. Coughlan AM, et al. 2016. Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells Dev. 2016, 25(7):530-541.